• Return to Headlines

Relatively Good Performance Detected in Shares of Esperion Therape in the Biotechnology Industry (ESPR , LXRX , BCRX , TGTX , EPZM )

By James Quinn

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.

Esperion Therape (NASDAQ:ESPR ) ranks first with a gain of 11.73%; Lexicon Pharmace (NASDAQ:LXRX ) ranks second with a gain of 6.86%; and Biocryst Pharm (NASDAQ:BCRX ) ranks third with a gain of 4.27%.

Tg Therapeutics (NASDAQ:TGTX ) follows with a gain of 4.07% and Epizyme Inc (NASDAQ:EPZM ) rounds out the top five with a gain of 4.06%.

SmarTrend recommended that subscribers consider buying shares of Epizyme Inc on January 4th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $6.98. Since that recommendation, shares of Epizyme Inc have risen 73.4%. We continue to monitor Epizyme Inc for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: relative performance esperion therape lexicon pharmace biocryst pharm tg therapeutics epizyme inc

Ticker(s): ESPR LXRX BCRX TGTX EPZM